Khyber Medical University (KMU) has finalized plans to conduct clinical trials of a new, indigenously developed herbal medicine for the treatment of cutaneous leishmaniasis (CL), a disfiguring skin disease increasingly prevalent in Khyber Pakhtunkhwa. The trials aim to evaluate the effectiveness of this herbal ointment as a potential alternative or adjunct to current treatments.
Trial Design and Methodology
The clinical trial, expected to last approximately six months, will involve three patient groups undergoing different treatment regimens. According to Dr. Khalid Rehman, Director of Public Health at KMU, the treatment modules will include:
- Standard glucantime injections
- Photodynamic therapy (PDT) in collaboration with Irnum Hospital
- Application of the locally prepared herbal medicine
Location and Scope
The trials will be conducted in a region highly affected by CL, with Malakand district being the preferred location. This strategic location will allow for the inclusion of patients from the adjacent districts of Bajaur and Mohmand, where a significant number of CL cases have been reported. The study aims to provide comprehensive data on the herbal medicine's efficacy across a diverse patient population within the affected region.
Addressing a Critical Need
Cutaneous leishmaniasis poses a significant public health challenge in Khyber Pakhtunkhwa, causing painful skin lesions and potential disfigurement. The development and testing of new treatment options, such as this herbal medicine, are crucial to addressing this growing health concern and improving patient outcomes.
